JO3442B1 - مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) - Google Patents

مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Info

Publication number
JO3442B1
JO3442B1 JOP/2014/0283A JOP20140283A JO3442B1 JO 3442 B1 JO3442 B1 JO 3442B1 JO P20140283 A JOP20140283 A JO P20140283A JO 3442 B1 JO3442 B1 JO 3442B1
Authority
JO
Jordan
Prior art keywords
sstr5
antagonists
compound
receptor subtype
somatostatin receptor
Prior art date
Application number
JOP/2014/0283A
Other languages
English (en)
Inventor
Shizuo Kasai
Hideki Hirose
Asato Kina
Tohru Yamashita
Yoichi Nishikawa
Takeshi Yamasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3442B1 publication Critical patent/JO3442B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<strong>يتعلق الاختراع الحالي بتوفير مركب له فعل مضاد </strong><span dir="LTR">SSTR5</span><strong> واستخدام المركب كدواء. على وجه التحديد، مركب يتم التعبير عنه بواسطة الصيغة التالية:</strong> <span dir="LTR"><img alt="??????? PT38-0003 ?????? 2013-20982620131007----00850075251302101257??20131007102827201310071027595150__________PT_84" src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></span> <strong>حيث يكون كل رمز كما تم التحديد في هذه الوثيقة،</strong> <strong> أو ملح منه، ويتم توفير دواء يشتمل على المركب أو ملح منه، واستخدام المركب أو ملح منه كعامل للوقاية من أو علاج مرض السكر. </strong>
JOP/2014/0283A 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) JO3442B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
JO3442B1 true JO3442B1 (ar) 2019-10-20

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0283A JO3442B1 (ar) 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Country Status (24)

Country Link
US (2) US9353108B2 (ar)
EP (1) EP3055309B1 (ar)
JP (1) JP6411520B2 (ar)
CN (1) CN105612158B (ar)
AR (1) AR097932A1 (ar)
BR (1) BR112016007620B1 (ar)
CA (1) CA2926544C (ar)
CY (1) CY1121163T1 (ar)
DK (1) DK3055309T3 (ar)
ES (1) ES2687102T3 (ar)
HR (1) HRP20181372T1 (ar)
HU (1) HUE039386T2 (ar)
JO (1) JO3442B1 (ar)
LT (1) LT3055309T (ar)
PL (1) PL3055309T3 (ar)
PT (1) PT3055309T (ar)
RS (1) RS57743B1 (ar)
RU (1) RU2671958C2 (ar)
SI (1) SI3055309T1 (ar)
SM (1) SMT201800461T1 (ar)
TR (1) TR201810506T4 (ar)
TW (1) TWI648276B (ar)
UY (1) UY35774A (ar)
WO (1) WO2015052910A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605000B2 (en) * 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN107001332B (zh) * 2014-12-02 2020-05-15 豪夫迈·罗氏有限公司 哌啶衍生物
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
WO2021230264A1 (ja) * 2020-05-13 2021-11-18 株式会社スコヒアファーマ 胆道系疾患の診断補助・予防・治療剤
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
US20260151410A1 (en) * 2022-05-30 2026-06-04 Scinnohub Pharmaceutical Co., Ltd Tetrahydronaphthyridine Derivatives, Medicine Prepared Therefrom, and Applications Thereof in Preventing and Treating Adhesion-related Diseases
WO2024204277A1 (ja) * 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
EP1432708B1 (en) 2001-09-24 2005-11-30 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr－5拮抗剂的苄醚胺化合物
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
WO2010129729A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
PL3063139T3 (pl) 2013-10-29 2019-05-31 Takeda Pharmaceuticals Co Związek heterocykliczny

Also Published As

Publication number Publication date
RS57743B1 (sr) 2018-12-31
HUE039386T2 (hu) 2018-12-28
JP6411520B2 (ja) 2018-10-24
CN105612158B (zh) 2017-06-30
ES2687102T3 (es) 2018-10-23
US9751878B2 (en) 2017-09-05
TW201536784A (zh) 2015-10-01
EP3055309B1 (en) 2018-06-13
UY35774A (es) 2015-05-29
RU2671958C2 (ru) 2018-11-08
PL3055309T3 (pl) 2018-10-31
BR112016007620A2 (pt) 2017-08-01
HRP20181372T1 (hr) 2018-10-19
US9353108B2 (en) 2016-05-31
US20150099777A1 (en) 2015-04-09
DK3055309T3 (en) 2018-08-27
CA2926544C (en) 2021-07-06
PT3055309T (pt) 2018-10-01
BR112016007620B1 (pt) 2020-05-26
CA2926544A1 (en) 2015-04-16
EP3055309A1 (en) 2016-08-17
SI3055309T1 (sl) 2018-10-30
WO2015052910A1 (en) 2015-04-16
LT3055309T (lt) 2018-08-27
TWI648276B (zh) 2019-01-21
CY1121163T1 (el) 2020-05-29
RU2016117732A (ru) 2017-11-15
AR097932A1 (es) 2016-04-20
TR201810506T4 (tr) 2018-08-27
JP2016531950A (ja) 2016-10-13
CN105612158A (zh) 2016-05-25
US20160237087A1 (en) 2016-08-18
SMT201800461T1 (it) 2018-11-09

Similar Documents

Publication Publication Date Title
PH12016501582A1 (en) Fused heterocyclic compound
PH12016501614A1 (en) Heterocyclic compound
MX2019010531A (es) Compuesto peptidico.
CY1121163T1 (el) Ανταγωνιστες υποδοχεα σωματοστατινης υποτυπου 5 (sstr5)
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
MX2016004088A (es) Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
TN2016000567A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
MY152946A (en) Fused ring compound and use thereof
AR128158A2 (es) Compuesto heterocíclico
EA201370149A1 (ru) Антагонисты рецептора
TN2017000097A1 (en) Heterocyclic compound
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof
IN2013MU02610A (ar)
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5&#39;-бромуридил-1&#39;-)етилен з потенційними фізіологічними властивостями
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями